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Abstract
Background: Patients with chronic obstructive pulmonary disease (COPD) are often nonadherent with medications
and have poor inhaler technique. Community pharmacists can help to improve health-related quality of life and
overall outcomes in patients with COPD. We aim to measure the effectiveness of a systematic, pharmacist-driven
intervention on patients with diagnosed COPD.
Methods/design: This pragmatic, parallel-group, cluster randomized controlled trial is designed to determine the
effectiveness of a multifactorial, pharmacist-led intervention on medication adherence, inhaler technique, health-
related quality of life, health care resource utilization including COPD exacerbations, and use of medications.
Participating pharmacies in Newfoundland and Labrador (NL), Canada will be randomly assigned to either the
intervention or the control group. The intervention group will deliver an enhanced form of care that emphasizes
COPD management. The control group will provide usual care and a COPD education pamphlet. Included patients
will be aged 40 years or older, have a physician-confirmed diagnosis of COPD, and be able to answer
questionnaires in English. The primary outcomes are the between-group difference in the change from baseline to
6 months in medication adherence using the Medication Possession Ratio (MPR) and the Morisky Medication
Adherence Scale (MMAS-8). The secondary outcomes are also measured from baseline to 6 months, and include
the proportion of patients with a clinically significant change in adherence, the proportion of patients defined as
having “good adherence,” the mean MPR between groups, quality of life as measured by the St. George’s
Respiratory Questionnaire, medication inhalation technique using a pharmacist-scored checklist, health care
resource utilization and antibiotic and orally administered corticosteroid use for COPD exacerbations. Differences
between groups will be analyzed at the individual patient level while controlling for clustering effect.
Discussion: A pharmacist-led COPD intervention has the potential to improve patient medication adherence, thus
increasing quality of life, possibly decreasing pulmonary exacerbations and reducing utilization of acute health care
resources. Methods and results taken from this study could be used to enhance the delivery of COPD care by
community pharmacists in a real-world setting. This would serve to enhance COPD population health and quality
of life.
Trial registration: International Standard Randomized Controlled Trial Number (ISRCTN) ISRCTN78138190,
registered on 3 February 2016.
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Chronic obstructive pulmonary disease (COPD) is a re-
spiratory disease characterized by a state of chronic in-
flammation, usually as a result of environmental toxins,
leading to a progressive loss of airway function and sys-
temic comorbidities [1, 2]. COPD is a significant cause
of morbidity and mortality and also represents a high
economic and social burden [3]. It is listed as the fifth
leading cause of death in the world [4], and the fourth
leading cause of death in Canada [5]. The overall societal
cost of COPD in Canada in 2011, including direct and
indirect costs of the disease, was CAN $4.52 billion [6].
Moreover, COPD exacerbations account for more than
50 % of the total health system costs of COPD [2, 7].
The prevalence of COPD is increasing, and although a
large proportion of patients remain undiagnosed, they
contribute a comparable health care burden to those
who have been diagnosed [8].
The approach to COPD management is multifactorial
and consists of nonpharmacological as well as pharma-
cological strategies in order to reduce symptoms, im-
prove quality of life, reduce exacerbations, and slow
disease progression [1, 2, 9, 10]. Unfortunately, rates of
adherence for medication use in those with COPD are
particularly low. The World Health Organization esti-
mates a 50 % adherence rate for patients with COPD
[11], while many studies report adherence rates in clin-
ical practice to be between 40 and 60 % [12–17]. There
are factors unique to COPD that predispose patients to
adherence issues, including the chronic nature of the
disease, complex medication regimens, significant co-
morbidities, and periods of disease stability between
exacerbations [16, 18].
Nonadherence has a significant impact on a patient’s
outcome, increasing hospitalization and exacerbation
rates [10, 19, 20]. Indeed, multiple studies have shown
an association between nonadherence in COPD and
clinical and economic outcomes [21]. A post-hoc ana-
lysis of the Towards a Revolution in COPD (TORCH)
trial indicated that patients with more than 80 % adher-
ence had a mortality rate of 11.3 % as compared to 26.4
% in those with adherence of 80 % or below with annual
hospitalization rates for exacerbations being 0.15 for ad-
herent patients and 0.27 for nonadherent patients [10].
Furthermore, another study indicated that better adher-
ence was associated with a 20 % reduction in annual
hospitalizations [20].
Pharmacists, as readily accessible primary health care
professionals with frequent interactions with patients,
play a unique role in the health care system. Moreover,
community pharmacies can act as cost-effective primary
care platforms for improving medication adherence, in-
halation technique, and health-related quality of life in
COPD [22–25]. A multifactorial, individualized approach
to COPD treatment has been suggested by many studies
[2, 15, 16, 22–25], with pharmacists playing a major role.
Our multifactorial intervention represents the highest
level of care available to COPD patients within the current
scope of practice of pharmacists in Newfoundland and
Labrador (NL), Canada, and allows us to compare the best
possible care to the current level of care provided to
COPD patients in the community.
Objectives
The primary objective of this study is to test the effect of
a multifactorial intervention at the community pharmacy
level on patient adherence to respiratory medications in
patients with COPD. Secondary objectives include asses-
sing the impact of the intervention on quality of life,
inhaler technique, and the sustainability and cost-
effectiveness of these enhanced services. We hypothesize
that the intervention will lead to improved adherence
and more effective use of medication such as: better in-
halation technique, and being prescribed more appropri-
ate therapy for disease severity.
Trial design
This trial is a pragmatic, parallel-group, cluster random-
ized controlled trial (RCT). Pharmacies will be allocated
in a 1:1 ratio, and the data analyzed using the individual
as the unit of analysis according to a superiority frame-
work. A completed Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) checklist
for the trial is available (see Additional file 1).
Methods/design
Study setting
The following study will be implemented in commu-
nity pharmacies throughout NL. A complete list of
study sites as of September 2016 is available in
Additional file 2.
Eligibility criteria
Inclusion restrictions were minimized in order to retain
the pragmatic nature of the study design. All community
pharmacies in NL holding a valid pharmacy licence will
be eligible to participate.
The patient inclusion criteria are as follows:
1. Physician-diagnosed COPD
2. Age 40 years or older at trial enrollment
3. The ability to answer questionnaires in English
Patients will not be eligible to participate in the study
if they have:
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1. Severe disease, defined as a known Forced
Expiratory Volume in 1 s (FEV1)/Forced Vital
Capacity (FVC) of below 30 %
2. A diagnosis of dementia or a prescription for
cholinesterase inhibitors
3. A terminal illness
4. Physician-diagnosed asthma
5. Participation in another clinical trial
6. They do not provide consent
Interventions
Staff pharmacists working at all participating pharmacies
from both arms of the study will be offered training on
the design of the study, including how to administer
questionnaires, proper patient recruitment, and consent-
ing of patients. The intervention group pharmacists will
also receive additional training on how to administer the
intervention to a patient as well as an overall “refresher”
on COPD management. In the event that additional staff
pharmacists at the recruited pharmacies are interested
in participating in the study, they will be provided with
the required training as needed, (see Additional files 3,
4, and 5 for training materials).
Interested patients will be identified through the use
of inhaled medication or a known diagnosis of COPD.
Posters and shelf-talkers will also be used to direct inter-
ested patients to the pharmacist for screening. The
recruiting pharmacist will determine whether or not the
patient meets the study criteria. The pharmacist will col-
lect relevant information from the patient directly, or
from their physician by telephone or fax in order to
complete the Patient Screening Form. Figure 1 provides
a flow chart of the consent and data collection process.
Data collection and delivery of the intervention may be
Fig. 1 Study Flow Diagram
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split into two pharmacy visits of no more than 2 weeks
apart.
Our intervention will be administered to patients at
their usual pharmacy after consent is obtained. The
intervention involves six main strategies in addition to
the COPD education pamphlet (see Additional file 6);
(1) medication review, (2) patient education, (3) a writ-
ten COPD Action plan provided in collaboration with
their family physician (see Additional file 7), (4) patient
referral to pulmonary rehabilitation in collaboration with
their family physician, (5) provision of, or referral to,
smoking cessation counseling (where applicable), and (6)
referral to a community-based chronic disease self-
management program.
1. Medication review
Patients will have a thorough review of their current
COPD medications. The review will consist of
current medications, doses, dosage forms, duration
and timelines of therapy, appropriateness of therapy,
and patient expectations. Drug-related problems will
be identified and recorded, and recommendations
for their resolution will be forwarded to the patient’s
primary health care provider
2. Patient education
The education will consist of evaluating current
inhaler technique and the subsequent correction or
teaching where required. Pharmacists will also
deliver adherence support strategies by determining
knowledge deficits, understanding the patient’s
expectations of their COPD therapy, and focusing
on teaching about medications and administration
techniques. The “teach-back technique” will be used
[26–28]
3. COPD Action Plan
A written “COPD Action plan” Form will be
provided and explained to the patient. This action
plan will inform the patient how to proceed when
COPD symptoms worsen. This action plan will be
developed in conjunction with the patient’s
physician, where patients do not already have a
standing prescription for antibiotics and oral
steroids. The form is divided into two sections, each
section having three subcategories. These include:
(1) “My Symptoms” (I feel well, I feel worse, I feel
much worse) and (2) “My Actions” (stay well, take
action, call for help). This action plan is easy to read
and simple to follow [29]. A copy of this will be
provided to the patient and to the patient’s physician
(faxed). When needed, a prescription suggestion for
antibiotics and oral steroids will be provided to the
physician for signature and fax back to the
pharmacy, to facilitate the action plan
4. Pulmonary Rehabilitation
In NL, access to specialized personnel or services is
usually achieved through referral by the family
practitioner. As such, all patients will have a request
for referral to pulmonary rehabilitation sent to their
family physician
5. Smoking cessation
Pharmacists will also refer current smokers to
smoking cessation services, or offer smoking
cessation counseling within the pharmacy, where
available
6. Community-based chronic disease self-management
program
Pharmacists will refer all patients to the community-
based chronic disease self-management program,
“Improving Health My Way.”
Patients attending pharmacies assigned to the
control group will receive a pamphlet on COPD and
usual care according to the clinical judgment of the
participating pharmacist. Care will not be limited or
directed by the study team in any way. Patients will
be able to withdraw from the study at any time.
Research staff will be available to participating
pharmacists to answer questions or provide support
as necessary.
Outcomes
The primary outcome is the difference in the change in
the MPR from baseline to 6 months between the inter-
vention and control groups. The World Health
Organization (WHO) has defined adherence to long-
term therapy as “the extent to which a person’s behavior
(taking medication, following a diet, and/or executing
lifestyle changes) corresponds with agreed recommenda-
tions from a health care provider” [30].
Medication adherence will be measured using both the
Medication Possession Ratio (MPR) and the Morisky
Medication Adherence Scale (MMAS-8) at baseline and
after 6 months of follow-up. The MPR is the ratio of
days of medication supplied over the 6-month follow-up
[31], which will be calculated using prescription records
collected from participating pharmacies. Prescription
record data will be kept on all of the patient’s prescrip-
tions. As in previous studies, a 10 to 15 % change in the
MPR will be considered a minimal clinically important
change [31, 32].
The MMAS-8 is a commonly used, validated, four-
item, self-reported adherence measure that has been
shown to be predictive of adherence to cardiovascular
medications and blood pressure control [33, 34]. The
minimal clinically important difference of the MMAS-8
is defined as a change of at least 2 points [35]. Secondary
adherence outcomes include the proportion of patients
with a clinically significant change in adherence, the pro-
portion of patients defined as having “good adherence”
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and the mean MPR between groups. Similar to others,
we will consider a threshold for good adherence to be an
MPR of at least 80 % or a MMAS-8 score of 8 or greater
[36, 37].
Secondary outcomes will be measured at baseline and
6 months and include: (1) quality of life, assessed by the
St. George’s Respiratory Questionnaire, (2) medication
inhalation technique using a pharmacist-scored scale, (3)
health care resource utilization (frequency of physician
visits, hospitalizations, emergency department visits, and
pharmacy visits) as reported by the patient at 6 months,
and (4) antibiotic and orally administered corticosteroid
use for acute exacerbations of COPD (AECOPD) as
reported by the patient at 6 months.
Participant timeline
Patients will be recruited over a 12-month period be-
tween May 2016 and May 2017 and will be followed for
6 months. See Fig. 1 for an overview of the participant
process.
Sample size calculation
We based our sample size calculation on our primary out-
come of change in adherence measured using the MPR.
We assumed a baseline adherence of 50 % [16, 38], a min-
imal detectable difference of a 14 % absolute change, a
standard deviation of 30 %, a correlation of 0.6 between
baseline and follow-up measurement, a type 1 error rate
of 5 %, a type 2 error rate of 20 %, and an intraclass correl-
ation coefficient of 0.05 [39]. We corrected for correlation
amongst patients within clusters using the inflation factor
1 + p(m − 1) where m is the mean number of observations
per cluster and p is the intraclass correlation. We esti-
mated that approximately 140 patients within at least 20
clusters would need to be enrolled to detect a 14 % change
in adherence with 80 % power. We will maintain a cluster
size of 20 pharmacies (10 intervention and 10 control)
and aim to enroll seven patients per pharmacy, or 140 pa-
tients in total. The sample size for our study will, there-
fore, have 80 % power to detect a minimum difference of
a 14 % change between the intervention and control
groups.
Recruitment
Pharmacists will be recruited primarily via email through
the provincial pharmacy associations, with follow-up
email and mail requests as needed. Patients presenting
with a new prescription or refill for COPD medications
will be approached by the pharmacist to gauge their
interest in participating in the study.
We will provide ongoing support and work closely
with pharmacies to ensure that recruitment targets are
appropriate for the community they serve. Moreover, we
will aim to monitor the recruitment process through
regular communication via site visits, telephone calls,
and emails to discuss any issues or challenges that might
arise.
Randomization
Randomization will be at the level of the community
pharmacy. A random number list will be generated using
Excel 2013 (Microsoft Corporation) and pharmacies will
be assigned to either intervention or control in a 1:1
ratio by the research assistant as they are recruited.
Blinding
It will not be possible for participating pharmacies to be
blinded to which group they are assigned due to the
nature of the intervention. The data analyst will be
blinded to treatment assignment.
Data collection methods
Pertinent demographic and contact information for par-
ticipating pharmacies will be recorded. Patient study
data will be collected using Data Collection Forms after
pharmacists obtain their consent. Follow-up will last for
6 months after enrollment and the delivery of the inter-
vention or usual care. All information will be stored at
the pharmacy. The research assistant will collect the in-
formation in hardcopy or by fax for data entry. A
blinded data analyst will conduct the final analysis.
Data collected will include: basic contact information
(name, mailing address, email, and phone/cell number)
as well as information related to the outcomes of the
study, including questionnaires and prescription and
health care resource utilization information. The Data
Collection Forms are to be completed by the patient and
pharmacist at baseline and 6 months. The research as-
sistant will be available to assist in the completion of
Data Collection Forms at the request of the pharmacist.
Any harms reported by the participants will be recorded
and included in the final manuscript.
Data management
Patient information will be coded using unique numer-
ical identifiers assigned by the research staff. All data en-
tered electronically will be identified only by this code,
and the master list will be kept in a locked cabinet in
the locked office of the principal investigator. All elec-
tronic information will be kept in an encrypted file.
Statistical methods
Baseline characteristics will be compared between the
intervention and control groups at the pharmacy (cluster
level) and patient level to assess for possible cluster im-
balances. Differences in the primary and secondary out-
comes of interest between the intervention and control
groups will be measured at 6 months using the
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individual as the unit of analysis. Generalized linear
mixed models will be used to account for the clustering
effect at the pharmacy level. We will assume an ex-
changeable correlation structure, calculate robust stand-
ard errors, and specify the appropriate outcome
distribution and link function for each model (e.g., bino-
mial distribution and logit link function for dichotomous
variables and a Gaussian distribution and identify link
function for continuous variables). In addition to an un-
adjusted analysis, we will conduct a secondary analysis
to adjust for potential differences in multiple baseline
covariates at both the pharmacy level (e.g., pharmacy
type, location, prescription volume, pharmacist to tech-
nician ratio) and the patient level (e.g., age, sex, baseline
medication knowledge, baseline adherence, baseline in-
haler technique). Standard model diagnostics will be
conducted to check for model assumptions. All analysis
will be intention-to-treat. Multiple imputation will be
used to account for missing data.
Protocol amendments
Any protocol amendments will be submitted to the NL
Health Research Ethics Board for approval and noted in
the registered protocol at the International Standard
Randomized Controlled Trial Number (ISRCTN) regis-
ter. Trial participants will be notified should relevant
protocol changes be made.
Access to data
All investigators, research assistants, and data analysts
will have access to the trial data.
Discussion
This study protocol presents the design of a pragmatic,
cluster RCT to determine the effectiveness of a multifac-
torial pharmacist-driven intervention on medication ad-
herence, inhaler technique, health-related quality of life,
health care resource allocation, and use of medications
including orally administered steroids and antibiotics
during the study period.
COPD management in Canada remains suboptimal,
with significant care gaps and patients experiencing poor
outcomes and high exacerbation rates [40]. COPD has
received considerably less attention in adherence re-
search than asthma, diabetes, cardiovascular disease, and
other chronic health conditions [41]. Thus, there is a
need for additional evidence with regards to therapy ad-
herence in COPD patients. Several adherence interven-
tions have been studied in RCTs, but few of these have
focused on COPD patients. Viswanathan et al, identified
62 RCTs in a systematic review, representing 18 different
interventions designed to improve adherence to medica-
tions for chronic diseases [42]. However, none of the
reviewed studies included COPD or addressed
polypharmacy.
Chronic disease management would be assumed to be
most successful when care is given through collaboration
of health care team members and patients, and includes
patient education and monitoring. Viswanathan et al.
[42] concluded that the collaborative care approach was
particularly effective in improving adherence. This has
potential application for the treatment of COPD.
In a literature search of adherence interventions [43],
key limitations in many studies addressing adherence re-
volve around three main points: reliance on inadequate
adherence measures; inclusion of a convenient sample of
patients; and assessments of intervention outcomes arti-
ficially boosted by attrition of least adherent participants.
Our study overcomes these limitations; first by depend-
ing on pharmacy management software, giving insight
into patient adherence; second by appropriate
randomization to include a wide range of COPD patients
through broad inclusion criteria and a follow-up plan;
and third by assessing our primary outcome through
both the MPR and the MMAS-8.
Additional strengths of our study include the prag-
matic design of the study which allows the observed
process to reflect real-world practice as accurately as
possible. Systematic recruitment of participants via com-
munity pharmacies will increase the trial’s internal valid-
ity. Moreover, our choice of cluster randomization at the
level of the pharmacy decreases the potential for con-
tamination of the control as each pharmacist in either
the intervention group or the control group will only be
providing either usual care or the intervention, not both.
Our intervention, though comprehensive, is relatively
simple and easily applicable to the clinical setting and
addresses both patient behavior and also the pharmacist-
patient relationship. We will also measure outcomes be-
yond adherence alone, including disease-focused and
patient-focused outcomes (e.g., health care resource
utilization and quality of life).
There are also limitations of this study design. We are
measuring our primary outcome indirectly via pharmacy
records (MPR) and patient self-report (MMAS-8). Al-
though the MMAS-8 tool has been validated, using dir-
ect adherence assessment tools, such as biochemical
markers, respiratory device counters or electronic pill-
boxes, may potentially provide more accurate results.
However, utilizing biochemical tests or potentially cum-
bersome respiratory device counters to measure adher-
ence would be costly and impractical and would require
repeat hospital visits and participant inconvenience,
which would detract from the pragmatic nature of this
study. There is also the potential for patients to interfere
with respiratory device counters and thus they may not
reliably provide superior measurement of adherence
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compared to the MPR and the MMAS-8. Another limi-
tation includes potential selection bias due to pharma-
cists preferentially recruiting patients who they know are
at higher risk of medication nonadherence to interven-
tion pharmacies.
There will be no publication restrictions for the full
trial results, and publication will be sought in peer-
reviewed journals. The authors plan to hold stakeholder
meetings to disseminate study results, as well as present
the results at local and national conferences.
Trial status
Pharmacy recruitment and intervention training began
in February 2016 and patient recruitment began in May
2016.
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